F. Ruzzi, L. Scalambra, M. S. Semprini, O. M. Pittino, C. Cappello, S. Angelicola, A. Palladini, P. Nanni, C. Fougeroux, L. Goksøyr, A.F. Sander, P.L. Lollini
{"title":"通过基于病毒样颗粒 (VLP) 的创新疫苗,靶向 9 型枯草蛋白酶/kexin (PCSK9),提高 HER-2 阳性乳腺癌临床前模型中 HER-2-VLP 疫苗的抗肿瘤活性","authors":"F. Ruzzi, L. Scalambra, M. S. Semprini, O. M. Pittino, C. Cappello, S. Angelicola, A. Palladini, P. Nanni, C. Fougeroux, L. Goksøyr, A.F. Sander, P.L. Lollini","doi":"10.1016/j.ejca.2024.113822","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":505596,"journal":{"name":"European Journal of Cancer","volume":"213 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), through an innovative virus-like particles (VLP)-based vaccine, enhance the antitumoral activity of a HER-2-VLP vaccine in a preclinical model of HER-2 positive breast cancer\",\"authors\":\"F. Ruzzi, L. Scalambra, M. S. Semprini, O. M. Pittino, C. Cappello, S. Angelicola, A. Palladini, P. Nanni, C. Fougeroux, L. Goksøyr, A.F. Sander, P.L. Lollini\",\"doi\":\"10.1016/j.ejca.2024.113822\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":505596,\"journal\":{\"name\":\"European Journal of Cancer\",\"volume\":\"213 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ejca.2024.113822\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ejca.2024.113822","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), through an innovative virus-like particles (VLP)-based vaccine, enhance the antitumoral activity of a HER-2-VLP vaccine in a preclinical model of HER-2 positive breast cancer